Ukr.Biochem.J. 2025; Volume 97, Issue 6, Nov-Dec, pp. 46-54

doi: https://doi.org/10.15407/ubj97.06.046

Inflammatory cytokines profile and oxidative stress markers in the serum of albino rats injected with macrophage migration inhibitory factor

16.12.2025   Uncategorized

N. T. Guliyeva1, S. V. Guliyeva2*, R. A. Akhundov2,
N. R. Jabbarova3, T. A. Eyvazov2

1Department of Cytology, Embryology and Histology,
Azerbaijan Medical University, Baku, Azerbaijan;
2Research Center, Azerbaijan Medical University, Baku, Azerbaijan;
3Department of Health Care Organization,
Azerbaijan Medical University, Baku, Azerbaijan;
*e-mail: quliyevasevda789@gmail.com

Received: 09 July 2025; Revised: 28 August 2025;
Accepted: 28 November 2025; Available on-line:  23 December 2025

Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine involved in the regulation of inflammation, immune responses, and redox homeostasis. However, its metabolic effects in experimental models remain insufficiently characterized. The aim of the work was to estimate the effect of recombinant MIF on cytokines profile, antioxidant defense markers and LPO indicators at different time points following its single intraperitoneal administration to albino rats. Animals were divided into a control group (n = 20) and three experimental groups (n = 10 each) assessed in 2, 3, and 14 days after MIF administration (10 µg/kg of b.w.), respectively. Serum samples were analyzed for IL-6, IL-10, TNF-α, IL-4, antioxidant markers and LPO products levels by ELISA and standard biochemical assays. It was shown that MIF administration induced time-dependent pro-inflammatory and pro-oxidant effects. Early compensatory anti-inflammatory responses were marked by increased IL-10 and decreased IL-6 levels. However, at the later stages (days 3 and 14), IL-6 and TNF-α elevation, along with IL-4 suppression, indicated a shift toward chronic inflammation. Antioxidant parameters progressively declined, with maximal suppression observed on day 14. Concurrently, a significant accumulation of LPO products confirmed sustained oxidative stress and membrane damage. These findings underscore the potential of MIF as a pharmacological target for the treatment of chronic inflammatory and metabolic disorders.

Keywords: , , , , ,

References:

  1. Jankauskas SS, Wong DWL, Bucala R, Djudjaj S, Boor P. Evolving complexity of MIF signaling. Cell Signal. 2019;57:76-88. PubMed, CrossRef
  2. Günther S, Fagone P, Jalce G, Atanasov AG, Guignabert C, Nicoletti F. Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: from pathogenic factors to therapeutic targets. Drug Discov Today. 2019;24(2):428-439. PubMed, CrossRef
  3. Morand EF, Leech M. Macrophage migration inhibitory factor in rheumatoid arthritis. Front Biosci. 2005;10:12-22. PubMed, CrossRef
  4. Bilsborrow JB, Doherty E, Tilstam PV, Bucala R. Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus. Expert Opin Ther Targets. 2019;23(9):733-744. PubMed, PubMedCentral, CrossRef
  5. 5. Lue H, Kapurniotu A, Fingerle-Rowson G, Roger T, Leng L, Thiele M, Calandra T, Bucala R, Bernhagen J. Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal. 2006;18(5):688-703. PubMed, CrossRef
  6. Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA. Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ. J Invest Dermatol. 2015;135(11):2775-2784. PubMed, PubMedCentral, CrossRef
  7. Santos LL, Morand EF. Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis. Clin Chim Acta. 2009;399(1-2):1-7. PubMed, CrossRef
  8. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003;3(10):791-800. PubMed, PubMedCentral, CrossRef
  9. Lang T, Lee JPW, Elgass K, Pinar AA, Tate MD, Aitken EH, Fan H, Creed SJ, Deen NS, Traore DAK, Mueller I, Stanisic D, Baiwog FS, Skene C, Wilce MCJ, Mansell A, Morand EF, Harris J. Macrophage migration inhibitory factor is required for NLRP3 inflammasome activation. Nat Commun. 2018;9(1):2223. PubMed, PubMedCentral, CrossRef
  10. Kleemann R, Kapurniotu A, Frank RW, Gessner A, Mischke R, Flieger O, Jüttner S, Brunner H, Bernhagen J. Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J Mol Biol. 1998;280(1):85-102. PubMed, CrossRef
  11. Ahmed M, Miller E. Macrophage migration inhibitory factor (MIF) in the development and progression of pulmonary arterial hypertension. Glob Cardiol Sci Pract. 2018;2018(2):14. PubMed, PubMedCentral, CrossRef
  12. 1Chuang YC, Su WH, Lei HY, Lin YS, Liu HS, Chang CP, Yeh TM. Macrophage migration inhibitory factor induces autophagy via reactive oxygen species generation. PLoS One. 2012;7(5):e37613. PubMed, PubMedCentral, CrossRef
  13. Mangano K, Mazzon E, Basile MS, Di Marco R, Bramanti P, Mammana S, Petralia MC, Fagone P, Nicoletti F. Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach. Oncotarget. 2018;9(25):17951-17970. PubMed, PubMedCentral, CrossRef
  14. Morsi HK, Ismail MM, Gaber HA, Elbasmy AA. Macrophage Migration Inhibitory Factor and Malondialdehyde as Potential Predictors of Vascular Risk Complications in Type 2 Diabetes Mellitus: Cross-Sectional Case Control Study in Saudi Arabia. Mediators Inflamm. 2016;2016:5797930. PubMed, PubMedCentral, CrossRef
  15. Lue H, Thiele M, Franz J, Dahl E, Speckgens S, Leng L, Fingerle-Rowson G, Bucala R, Lüscher B, Bernhagen J. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene. 2007;26(35):5046-5059. PubMed, CrossRef
  16. Barnes MA, McMullen MR, Roychowdhury S, Madhun NZ, Niese K, Olman MA, Stavitsky AB, Bucala R, Nagy LE. Macrophage migration inhibitory factor is required for recruitment of scar-associated macrophages during liver fibrosis. J Leukoc Biol. 2015;97(1):161-169. PubMed, PubMedCentral, CrossRef
  17. Xu X, Sun B, Zhao C. Poly (ADP-Ribose) polymerase 1 and parthanatos in neurological diseases: From pathogenesis to therapeutic opportunities. Neurobiol Dis. 2023;187:106314. PubMed, CrossRef
  18. Ayala A, Muñoz MF, Argüelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev. 2014;2014:360438. PubMed, PubMedCentral, CrossRef
  19. Breidung D, Megas IF, Freytag DL, Bernhagen J, Grieb G. The Role of Macrophage Migration Inhibitory Factor (MIF) and D-Dopachrome Tautomerase (D-DT/MIF-2) in Infections: A Clinical Perspective. Biomedicines. 2023;12(1):2. PubMed, PubMedCentral, CrossRef
  20. Asakawa T, Matsushita S. Coloring condition of the thiobarbituric acid test for detecting lipid hydroperoxides. Lipids. 1980;15(3):137-140. CrossRef
  21. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82(1):70-77. PubMed, CrossRef
  22. Rice-Evans C, Miller NJ. Total antioxidant status in plasma and body fluids. Methods Enzymol. 1994;234:279-293. PubMed, CrossRef
  23. Methods of Enzymatic Analysis. Ed. Bergmeyer HU. Vol. 2. New York: Academic Press; 1974. CrossRef
  24. McHugh ML. The chi-square test of independence. Biochem Med (Zagreb). 2013;23(2):143-149. PubMed, PubMedCentral, CrossRef
  25. Figueiredo CR, Azevedo RA, Mousdell S, Resende-Lara PT, Ireland L, Santos A, Girola N, Cunha RLOR, Schmid MC, Polonelli L, Travassos LR, Mielgo A. Blockade of MIF-CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma. Front Immunol. 2018;9:1132. PubMed, PubMedCentral, CrossRef
  26. Mitchell RA. Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell Signal. 2004;16(1):13-19. PubMed, CrossRef
  27. Jarmula J, Lee J, Lauko A, Rajappa P, Grabowski MM, Dhawan A, Chen P, Bucala R, Vogelbaum MA, Lathia JD. Macrophage migration inhibitory factor as a therapeutic target in neuro-oncology: A review. Neurooncol Adv. 2024;6(1):vdae142. PubMed, PubMedCentral, CrossRef
  28. Gao L, Flores C, Fan-Ma S, Miller EJ, Moitra J, Moreno L, Wadgaonkar R, Simon B, Brower R, Sevransky J, Tuder RM, Maloney JP, Moss M, Shanholtz C, Yates CR, Meduri GU, Ye SQ, Barnes KC, Garcia JG. Macrophage migration inhibitory factor in acute lung injury: expression, biomarker, and associations. Transl Res. 2007;150(1):18-29. PubMed, PubMedCentral, CrossRef
  29. Koga K, Kenessey A, Powell SR, Sison CP, Miller EJ, Ojamaa K. Macrophage migration inhibitory factor provides cardioprotection during ischemia/reperfusion by reducing oxidative stress. Antioxid Redox Signal. 2011;14(7):1191-1202. PubMed, CrossRef
  30. Heinrichs D, Knauel M, Offermanns C, Berres ML, Nellen A, Leng L, Schmitz P, Bucala R, Trautwein C, Weber C, Bernhagen J, Wasmuth HE. Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74. Proc Natl Acad Sci USA. 2011;108(42):17444-17449. PubMed, PubMedCentral, CrossRef
  31. Wang SS, Cen X, Liang XH, Tang YL. Macrophage migration inhibitory factor: a potential driver and biomarker for head and neck squamous cell carcinoma. Oncotarget. 2017;8(6):10650-10661. PubMed, PubMedCentral, CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.